Kenza Samlali

Kenza Samlali is an accomplished researcher and entrepreneur with a robust background in biotechnology and applied synthetic biology. Currently serving as a member of the HQ Safety and Security Committee at iGEM and previously as a 5050 Fellow at Fifty Years, Kenza has contributed to the commercialization of therapeutic modalities. As Co-founder and Director of Product Development at Panoplia Laboratories, efforts focus on developing next-generation antivirals utilizing innate immune pathways. With a proven record in manufacturing, Kenza led the CMC strategy and drug manufacturing team at Alvea, successfully guiding projects from conception to clinical trial readiness. Kenza's academic credentials include a PhD from Concordia University, with notable research in microfluidics and single-cell engineering, alongside several publications and patents. Educational background also encompasses advanced degrees in Biological/Biosystems Engineering and Biology from prestigious institutions such as KU Leuven and Université de Montréal.